Baxter completes Seprafilm acquisition
DEERFIELD -- Baxter International has completed its acquisition of Seprafilm Adhesion Barrier and related assets from Sanofi for $350 million.
The Seprafilm product family, which is used as an adjunct to reduce the incidence, extent and severity of adhesions in certain pelvic and abdominal surgeries, currently has a global commercial presence in the U.S., Japan, China, South Korea and France, among other countries. Seprafilm has been more extensively evaluated than any other adhesion barrier and has been found to significantly reduce the incidence, extent, and severity of adhesions following abdominopelvic surgery.
"We are excited to bring Seprafilm products, alongside our leading hemostat and sealant portfolio, to our surgeon and hospital customers around the world," said Wil Boren, general manager, Baxter's Advanced Surgery business.